34 results about "Osteomalacia" patented technology

The present invention relates to compounds of Formula (I),

methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury/loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.

The present invention relates to compounds of Formula (I),

methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury/loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.

The invention relates to a preparation method of high soluble crystal calcium citrate in the fields of biochemical engineering, medicine and food. The technical scheme of the method comprises the following steps: (1) mixing citric acid, calcium carbonate and water, serving as raw materials, in a ratio of 3.84:3:1; (2) placing the mixture in a reaction tank at 20-50 DEG C after mixing, starting a machine to perform a chemical reaction for 50-60 minutes; (3) stopping the machine for 25-35 minutes to perform a chemical reaction for maturing; (4) starting the machine for 25-35 minutes to discharge high soluble crystal calcium citrate under the crystallization temperature; and (5) filtering, drying and packaging to obtain the finished product. The invention has the following beneficial effects: the molecular formula of the synthesized high soluble crystal calcium citrate is Ca3H3 (C6H5O7)2(HCO3)3, the solubility is 98%, the high solution type calcium citrate is soluble calcium and can be used to supplement calcium and cure osteoporosis and osteomalacia, human and animals can absorb the high soluble crystal calcium citrate easily; and the calcium citrate injection and calcium citrate oral liquid can also be used, and the use of the high soluble crystal calcium citrate is not limited by insoluble calcium citrate.

The present invention relates to compounds of Formula (I),

methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury/loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.

The invention relates to a preparation method of soluble strontium citrate in the field of biochemical and pharmaceutical foods. The technical scheme comprises the following steps of: uniformly mixing citric acid, strontium carbonate and water according to a mixing ratio; putting the uniformly mixed materials into a reaction kettle at 60-80 DEG C; starting up to carry out chemical reaction for 180-240 minutes; standing for 50-60 minutes until the chemical reaction is mature; stirring the materials in the reaction kettle for 60-70 minutes; discharging soluble strontium citrate at the crystallization temperature; filtering and drying the soluble strontium citrate; and then packaging the soluble strontium citrate to obtain a finished product. The preparation method of soluble strontium citrate, provided by the invention, has the following advantages that: the combined soluble strontium citrate with chemical structure molecular formula of Sr3(C6H5O7)2(H2CO3)3, which is white crystal powder, is a food feed additive medicine capable of treating osteoporosis and osteomalacia, easily absorbed by human and animals and used for preventing soluble strontium citrate injections and soluble strontium citrate oral liquids from being restricted by insoluble strontium citrate.

The invention mainly relates to a cancellous bone-invigorating formula for treating osteoporosis and a preparation technology thereof. The formula comprises the following raw materials by weight: 12-18 parts of radix rehmanniae praeparata, 13-17 parts of cornus officinalis, 10-14 parts of angelica sinensis, 14-16 parts of epimedium brevicornum maxim, 10-14 parts of semen cuscutae, 10-14 parts of medlar, 11-13 parts of rhizoma atractylodis macrocephalae and 11-13 parts of lumbricus. The cancellous bone-invigorating formula can treat the primary and secondary osteoporosis and osteomalacia effectively, takes significant curative effects on symptoms such as back, waist or whole body aching and tired, limb weakness, legs and feet cramp, deadlimb, dysphoria and irritability, palpitation and insomnia, sweating, a reddened tongue, yellowish coated tongue, a yellowish coatedtongue with crack and thready rapid pulse and the like due to deficiency of kidney-yin and blood stasis, and achieves remarkable effects of preventing bone mineral density from being reduced, reducing the bone turnover, and improving the balanced capacity. According to the invention, the preparation technology is simple, the production cost is low, and the curative effect of the drug prepared according to the formula is remarkable. Therefore, the formula and the preparation technology thereof are suitable for popularization and application.

The invention belongs to the technical field of medical treatment and especially relates to a formula of Xibixiao tincture, which includes: rhizoma corydalis, angelica sinensis, cynomorium songaricum,rhizoma chuanxiong, sappan wood, radix clematidis, and pawpaw. In the invention, the powders of the medicines including the rhizoma corydalis, angelica sinensis, cynomorium songaricum, rhizoma chuanxiong, sappan wood, radix clematidis and pawpaw are matched with baijiu, so that the product is used for tuina therapy on an injury position of a patient so as to absorb the medicine. The Xibixiao tincture is easy to use, has effects of soothing tendon and activating collateral, activating blood and relieving pain, and removing stasis and freeing meridian, can effectively treat diseases such as knee osteoarthritis, synovitis, osteoproliferation, chondromalacia patellae and knee joint sprain, and can effectively the pain of the patients.

Embodiments of the invention are directed to formulations comprising Cannabidiol (CBD) and glucosamine (Gln). Further embodiments of the invention are directed to methods of treating or preventing Arthritis, Osteoarthritis, Rheumatoid arthritis, Osteoporosis, Osteopenia, jaw pain, joint pain, knee pain, back pain, multiple sclerosis, Osteomalacia and Paget's disease of bone, wherein the method comprises administering a formulation comprising Cannabidiol (CBD) and glucosamine (Gln).

The method relates to a method for preparing taurine VC calcium citrate in the field of biochemistry, medicines and food. The method comprises the following steps: (1) uniformly mixing citric acid, calcium oxide, water, taurine and VC in a ratio of 7.68:4.48:1:5:7.04; (2) after uniform mixing, putting the mixture in a reactor at 20-50 DEG C and starting the reactor to carry out chemical reaction for 50-60 minutes; (3) stopping the reactor for 25-35 minutes to ensure the chemical reaction to be mature; (4) starting the reactor for 25-35 minutes to exhaust taurine VC calcium citrate under crystallization temperature; and (5) carrying out packaging after filtration and drying to obtain the finished product. The method has the following beneficial effects: the synthesized taurine VC calcium citrate has solubility as high as 98%, is soluble calcium, can be used for supplementing calcium and treating osteoporosis and osteomalacia, is easily absorbed by human and animals, can be used in the forms of calcium citrate injections and calcium citrate oral liquid and is not limited by indissolvable calcium citrate.

The invention discloses improved feed-grade calcium hydrogen phosphate. The improved feed-grade calcium hydrogen phosphate is prepared from the components in parts by weight: 100-200 parts of slaked lime, 30-40 parts of flour, 6-12 parts of rice bran, 1-5 parts of vegetable oil, 6-10 parts of hydrochloric acid, 1-3 parts of yellow mealworm sand, 2-6 parts of pomace and 8-12 parts of nutrition additives. The feed has the characteristics of high phosphorus content, high water solubility and the like, the growth and development of livestock and poultry can be accelerated, the fattening period isshortened, and weight is quickly gained; and the breeding rate and survival rate of the livestock and poultry can be improved, at the same time, the disease and cold resistance of the livestock and poultry is improved, and the preventive and therapeutic effect of osteomalacia, white dysentery and paralysis of the livestock and poultry is provided.

Provided is a pharmaceutical composition for preventing or treating metabolic bone diseases, containing bentonite as an active ingredient. The present disclosure relates to a composition for inhibiting bone resorption of osteoclasts and simultaneously, promoting bone formation of osteoblasts to be usable in the prevention or treatment of metabolic bone diseases such as osteoporosis, osteomalacia, osteopenia and bone atrophy.